CORT

Corcept Therapeutics stops depression drug trial

[Reuters] – Corcept Therapeutics Inc said it would stop a late-stage trial of its drug for depression after an interim analysis suggested the study was unlikely to be successful. The analysis of data from the first 226 patients enrolled in the trial show moreView todays social media effects on CORTView the latest stocks trending across Twitter. Click to view dashboardSee […]

8:34 am Corcept Therapeutics reports interim analysis of data from Phase 3 Trial of Mifepristone for the Treatment of psychotic depression fails to demonstrate efficacy with statistical significance (stock halted)

moreView todays social media effects on CORTView the latest stocks trending across Twitter. Click to view dashboardSee who Corcept is hiring next, click here to view […]

Corcept Therapeutics Announces First Quarter 2014 Financial Results

[Marketwired] – Corcept Therapeutics Incorporated , a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders, … moreView todays social media effects on CORTView the latest stocks trending across Twitter. Click to view dashboardSee who Corcept is hiring next, click here to view […]

Nasdaq stocks posting largest volume increases

moreView todays social media effects on CORTView the latest stocks trending across Twitter. Click to view dashboardSee who Corcept is hiring next, click here to view […]

Corcept Therapeutics Announces Fourth Quarter Results and Full Year Revenue and Corporate Update

[at noodls] – MENLO PARK, Calif. – February 12, 2013 Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment … moreView todays social media effects on CORTView the latest stocks trending across Twitter. Click to view dashboardSee who Corcept is hiring next, click here to view […]